Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitis
Latest Information Update: 17 Feb 2020
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Dr Falk Pharma
- 19 Oct 2016 Results of patients with impairment in work productivity (n=297) presented at the 24th United European Gastroenterology Week
- 30 May 2016 Status changed from active, no longer recruiting to completed.
- 23 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov